# UGCG

## Overview
The UGCG gene encodes the enzyme UDP-glucose ceramide glucosyltransferase, a crucial component in the biosynthesis of glycosphingolipids. This enzyme, categorized as a transmembrane protein, is primarily localized in the Golgi apparatus, where it catalyzes the conversion of ceramide to glucosylceramide, a precursor for complex glycosphingolipids (Hirabayashi2002GlcCer). These glycosphingolipids are integral to cellular membranes and play significant roles in cell signaling and interactions (Ishibashi2013New). UGCG is essential for maintaining epidermal barrier integrity and is involved in keratinocyte differentiation, impacting skin health (Amen2013Differentiation). Alterations in UGCG expression are linked to various pathological conditions, including cancer and lipid storage disorders, highlighting its clinical significance (Li2021Ceramide; Alfonso2013Characterization).

## Structure
The UGCG gene encodes the UDP-glucose ceramide glucosyltransferase enzyme, which is involved in the synthesis of glucosylceramide, a precursor for most glycosphingolipids. The enzyme is a membrane-bound protein localized in the Golgi apparatus, characterized by its hydrophobic nature and a molecular mass of approximately 38 kDa on SDS-polyacrylamide gels, although the cDNA sequence suggests a mass of about 45 kDa (Hirabayashi2002GlcCer). The enzyme's structure includes a transmembrane domain, with both the C terminus and a hydrophilic loop near the N-terminus positioned on the cytosolic side, indicating its orientation within the Golgi membrane (Hirabayashi2002GlcCer).

A key feature of UGCG is the presence of a histidine residue at position 193, which is crucial for binding UDP-glucose and the enzyme inhibitor PDMP (Hirabayashi2002GlcCer). The enzyme is suggested to form a dimer or oligomer with another protein within the Golgi membrane, although specific details on its quaternary structure are not fully elucidated (Hirabayashi2002GlcCer). Despite attempts to express the enzyme in large quantities for structural studies, high-level expression has proven toxic to host cells, complicating detailed structural analysis (Hirabayashi2002GlcCer).

## Function
UGCG (UDP-glucose ceramide glucosyltransferase) is an enzyme that plays a critical role in the biosynthesis of glycosphingolipids by catalyzing the conversion of ceramide to glucosylceramide (GlcCer) (Hirabayashi2002GlcCer; Ishibashi2013New). This reaction is essential for the formation of complex glycosphingolipids, which are important components of cell membranes and are involved in cellular processes such as cell signaling and cell-cell interactions (Hirabayashi2002GlcCer). UGCG is primarily active on the cytosolic face of the Golgi apparatus in mammalian cells, where it facilitates the synthesis of GlcCer (Ishibashi2013New).

In healthy human cells, UGCG is crucial for maintaining the integrity of the epidermal barrier. It is involved in the differentiation of epidermal keratinocytes by processing GlcCer, which is necessary for the proper formation of the cornified envelope and the maintenance of the skin's water permeability barrier (Amen2013Differentiation). Deficiency in UGCG leads to disruptions in keratinocyte differentiation and epidermal barrier function, resulting in skin abnormalities (Amen2013Differentiation). The enzyme's activity is also linked to the regulation of ceramide levels, which are important for cell survival and apoptosis (Ishibashi2013New).

## Clinical Significance
Alterations in the expression of the UGCG gene, which encodes UDP-glucose ceramide glucosyltransferase, have significant clinical implications in various diseases, particularly cancer. Overexpression of UGCG is linked to multidrug resistance in several cancer types, including breast cancer, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC). In breast cancer, UGCG overexpression is associated with poor prognosis and increased resistance to chemotherapy drugs like doxorubicin, mediated by enhanced expression of multidrug resistance protein 1 (MDR1) and P-glycoprotein 1 (P-gp) (Wegner2018UDPglucose; Li2021Ceramide). In NSCLC, high UGCG levels correlate with poor differentiation, metastasis, and chemotherapy resistance, making it an independent risk factor for survival (Li2021Ceramide). In HCC, UGCG overexpression contributes to tumorigenesis by affecting glycosphingolipid metabolism, and its inhibition can delay tumor progression (Li2021Ceramide).

UGCG is also implicated in lipid storage disorders such as Gaucher disease, where genetic variants can alter gene expression and disease severity (Alfonso2013Characterization). Inhibition of UGCG can lead to increased ceramide levels, promoting apoptosis in p53-deficient cancer cells, suggesting a potential therapeutic target for enhancing chemotherapy efficacy (Haynes2012DNA).

## Interactions
UGCG (UDP-glucose ceramide glucosyltransferase) is known to interact with several proteins, influencing various cellular processes. It forms complexes with proteins such as c-Fos and Reticulon-1C, although its enzymatic activity does not depend on these interactions (Wegner2018The). UGCG also interacts with B4GalT5 (beta-1,4-galactosyltransferase 5) in cardiomyocytes, forming a complex involved in glycosylation processes. This interaction is confirmed through immunoprecipitation and co-staining experiments, suggesting a role in myocardial hypertrophy and mitochondrial oxidative stress regulation (Cui2023UGCG).

UGCG's activity affects the expression of multidrug resistance protein 1 (MDR1) through the production of gangliosides, which activate the transcription factor NFΚB. This leads to increased MDR1 gene and P-gp protein expression, involving signaling pathways such as cSrc and β-catenin (Wegner2018The). UGCG overexpression in breast cancer cells is associated with increased phosphorylation of signaling proteins like Akt, GSK-3β, and ERK1/2, contributing to drug resistance and altered cell proliferation (Wegner2018UDPglucose). These interactions highlight UGCG's role in modulating cellular signaling pathways and its potential impact on disease processes such as cancer and heart hypertrophy.


## References


[1. (Wegner2018UDPglucose) Marthe-Susanna Wegner, Nina Schömel, Lisa Gruber, Stephanie Beatrice Örtel, Matti Aleksi Kjellberg, Peter Mattjus, Jennifer Kurz, Sandra Trautmann, Bing Peng, Martin Wegner, Manuel Kaulich, Robert Ahrends, Gerd Geisslinger, and Sabine Grösch. Udp-glucose ceramide glucosyltransferase activates akt, promoted proliferation, and doxorubicin resistance in breast cancer cells. Cellular and Molecular Life Sciences, 75(18):3393–3410, March 2018. URL: http://dx.doi.org/10.1007/s00018-018-2799-7, doi:10.1007/s00018-018-2799-7. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-018-2799-7)

[2. (Hirabayashi2002GlcCer) Yoshio Hirabayashi and Shinichi Ichikawa. GlcCer Synthase (UDP-Glucose:Ceramide Glucosyltransferase, UGCG), pages 3–8. Springer Japan, 2002. URL: http://dx.doi.org/10.1007/978-4-431-67877-9_1, doi:10.1007/978-4-431-67877-9_1. This article has 2 citations.](https://doi.org/10.1007/978-4-431-67877-9_1)

[3. (Alfonso2013Characterization) Pilar Alfonso, Joaquín Navascués, Silvia Navarro, Pilar Medina, Alfonso Bolado-Carrancio, Vanesa Andreu, Pilar Irún, José Carlos Rodríguez-Rey, Miguel Pocoví, Francisco España, and Pilar Giraldo. Characterization of variants in the glucosylceramide synthase gene and their association with type 1 gaucher disease severity. Human Mutation, 34(10):1396–1403, August 2013. URL: http://dx.doi.org/10.1002/humu.22381, doi:10.1002/humu.22381. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22381)

[4. (Wegner2018The) Marthe-Susanna Wegner, Lisa Gruber, Peter Mattjus, Gerd Geisslinger, and Sabine Grösch. The udp-glucose ceramide glycosyltransferase (ugcg) and the link to multidrug resistance protein 1 (mdr1). BMC Cancer, February 2018. URL: http://dx.doi.org/10.1186/s12885-018-4084-4, doi:10.1186/s12885-018-4084-4. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-018-4084-4)

[5. (Haynes2012DNA) Teka-Ann S. Haynes, Valery Filippov, Maria Filippova, Jun Yang, Kangling Zhang, and Penelope J. Duerksen-Hughes. Dna damage induces down-regulation of udp-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1821(7):943–953, July 2012. URL: http://dx.doi.org/10.1016/j.bbalip.2012.02.002, doi:10.1016/j.bbalip.2012.02.002. This article has 13 citations.](https://doi.org/10.1016/j.bbalip.2012.02.002)

[6. (Amen2013Differentiation) Nicole Amen, Daniel Mathow, Mariona Rabionet, Roger Sandhoff, Lutz Langbein, Norbert Gretz, Carsten Jäckel, Hermann-Josef Gröne, and Richard Jennemann. Differentiation of epidermal keratinocytes is dependent on glucosylceramide:ceramide processing. Human Molecular Genetics, 22(20):4164–4179, June 2013. URL: http://dx.doi.org/10.1093/hmg/ddt264, doi:10.1093/hmg/ddt264. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddt264)

[7. (Cui2023UGCG) Shengyu Cui, Xutao Zhang, Yuhua Li, Shan Hu, Bing Wu, Zhao Fang, Jixian Gao, Ming Li, Haoliang Wu, Bo Tao, Hao Xia, and Lin Xu. Ugcg modulates heart hypertrophy through b4galt5-mediated mitochondrial oxidative stress and the erk signaling pathway. Cellular &amp; Molecular Biology Letters, September 2023. URL: http://dx.doi.org/10.1186/s11658-023-00484-3, doi:10.1186/s11658-023-00484-3. This article has 2 citations.](https://doi.org/10.1186/s11658-023-00484-3)

[8. (Ishibashi2013New) Yohei Ishibashi, Ayako Kohyama-Koganeya, and Yoshio Hirabayashi. New insights on glucosylated lipids: metabolism and functions. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1831(9):1475–1485, September 2013. URL: http://dx.doi.org/10.1016/j.bbalip.2013.06.001, doi:10.1016/j.bbalip.2013.06.001. This article has 104 citations.](https://doi.org/10.1016/j.bbalip.2013.06.001)

[9. (Li2021Ceramide) Zibo Li, Lin Zhang, Dan Liu, and Caiyan Wang. Ceramide glycosylation and related enzymes in cancer signaling and therapy. Biomedicine &amp; Pharmacotherapy, 139:111565, July 2021. URL: http://dx.doi.org/10.1016/j.biopha.2021.111565, doi:10.1016/j.biopha.2021.111565. This article has 17 citations.](https://doi.org/10.1016/j.biopha.2021.111565)